Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Injection Therapies for Acromioclavicular Joint Pain
NCT05161468Phase 4Terminated
- Sponsor
- Brooke Army Medical Center
- Start
- Aug 2021
- Primary completion
- May 2025
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of autologous platelet-rich plasma in Acromioclavicular joint disorder (ACJD) (3 arms), sponsored by Brooke Army Medical Center. Primary endpoint: PROMIS Physical Function Scale Computer Adapted Test at 6 months. Started Aug 2021; status: terminated.
02
Drugs
autologous platelet-rich plasma
03
Conditions
Acromioclavicular joint disorder (ACJD)
Beyond the preview
Go deeper on NCT05161468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05161468.